France Faces Regulatory Hurdles Despite Overwhelming Support for Medical Cannabis

A recent Norstat survey shows that 92% of French citizens support the legalization of medical cannabis strictly for therapeutic purposes, particularly among patients with chronic pain, epilepsy, and cancer-related symptoms. Since the inception of an experimental medical cannabis program in 2021, about 700-750 patients have accessed cannabis treatments for conditions resistant to traditional therapies. However, enrollment for new patients ceased in March 2024, creating a "temporary legislative void" and raising concerns about unequal healthcare access.

The experimental phase was scheduled to conclude by the end of 2024 but has been extended until March 2025 to guarantee treatment continuity. A decisive regulatory decree is expected in June 2026, alongside a key opinion from the Haute Autorité de Santé regarding potential reimbursement for medical cannabis. Despite 57% of the public viewing medical cannabis as a necessary alternative to relieve suffering, 79% believe that misconceptions, often confusing medical and recreational use, obstruct progress in the debate.

Patient advocacy groups warn that slow regulatory responses clash with strong public opinion, emphasizing urgent access needs for seriously ill patients. Healthcare providers remain concerned about the legal uncertainty and the exclusion of new patients from treatment, highlighting the inequality in access across France. The government's cautious approach continues amid ongoing public demand.